You are here:

pasireotide (as pamoate) (Signifor)

Advice

In the absence of a submission from the holder of the marketing authorisation:

pasireotide (as pamoate) (Signifor ®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: pasireotide (as pamoate) (Signifor)
SMC Drug ID: 1311/18
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 February 2018

Back